查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363982

全球EB病毒診斷與治療市場2023-2030

Global Epstein-Barr Virus Diagnosis and Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 198 Pages | 商品交期: 2-3個工作天內

價格

預計全球 Epstein-Barr 病毒診斷和治療市場在預測期內（2023-2030 年）將以 5.1% 的年複合成長率成長。 EB 病毒 (EBV) 的廣泛流行是創造其治療需求的關鍵因素，進而推動全球 EBV 診斷和治療市場的發展。 EBV 是一種皰疹病毒，感染後通常作為有機體存在於咽喉上皮組織和淋巴細胞中。大多數人都攜帶該病毒，血液檢查通常會顯示低水平的 EBV 抗體。此外，多發性硬化症 (MS) 是一種無法治癒的自體免疫疾病，全世界有 280 萬人深受其苦。根據美國多發性硬化症協會的數據，被診斷出患有多發性硬化症的人的中樞神經系統會受到漸進性損害，並且可能會損失約七年的預期壽命。哈佛大學陳曾熙公共衛生學院的研究人員確定，感染該疾病的最大風險因素可能是先前感染過愛潑斯坦-巴爾病毒（EBV）。

細分市場前景

全球EB病毒診斷和治療市場按診斷和治療進行細分。根據診斷，市場分為基於實驗室的測試和 POC 測試。根據治療方法，市場細分為抗病毒藥物（阿昔洛韋、更昔洛韋、地昔洛韋）和其他藥物（抗發炎藥、退燒藥等）。在診斷中，照護端子細分市場預計將佔據相當大的市場佔有率。照護端測試工具在可在非診斷環境中診斷的適應症方面開闢了廣泛的選擇。實驗室。

抗病毒藥物子細分市場預計將在全球 Epstein-Barr 病毒診斷和治療市場中佔據相當大的佔有率

其中，抗病毒檢測細分市場預計將在全球EB病毒診斷和治療市場中佔據相當大的佔有率。抗病毒藥物是治療傳染病時最常用的藥物，也是主要傳染病之一。傳染性單核細胞增多症，也稱為“單核細胞增多症”，是一種傳染病。 EBV 是傳染性單核球增多症最常見的原因，但其他病毒也可能引起這種疾病。它在青少年和年輕人中很常見，尤其是大學生。感染 EBV 的青少年和年輕人中至少有四分之一會出現傳染性單核細胞增多症。已知可引起傳染性單核細胞增多症或單核細胞增多症的 EBV 感染史以及某些類型的癌症被認為是多發性硬化症 (MS) 最強的危險因子。

區域展望

全球EB病毒診斷和治療市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，北美預計將在全球市場中佔據顯著佔有率。自體免疫疾病病例的增加以及由此導致的抗體檢測需求的增加，以及政府為提高公眾對健康保險計劃優勢的認知而採取的舉措，是預計推動區域市場成長的一些關鍵因素。

亞太地區預計全球EB病毒診斷和治療市場將以顯著的年複合成長率成長

在所有地區中，亞太地區預計在預測期內將以可觀的年複合成長率成長。區域成長歸因於一般人口數量的增加以及由於該地區新疾病病例增加而導致的臨床試驗數量的增加。 2022 年 5 月，美國國立衛生研究院 (NIH) 旗下的國家過敏和傳染病研究所 (NIAID) 啟動了一項早期臨床試驗，以評估 Epstein-Barr 病毒 (EBV) 的研究性預防疫苗。 EBV 是傳染性單核球增多症（「單核球增多症」）的主要原因，並與某些癌症和自體免疫疾病有關。第一階段研究是十多年來僅有的兩項測試研究性 EBV 疫苗的研究之一。它將在馬裡蘭州貝塞斯達的 NIH 臨床中心進行。

因此，該國在採用 Epstein-Barr 病毒診斷和治療市場解決方案方面發生了重大轉變。據印度醫學研究委員會稱，中國於2020年4月向印度發送了50萬份快速抗體檢測試劑盒（ICMR）。此外，中國研發公司更專注於開發生物特異性抗體測試，而大多數外國公司主要關注抗CD3抗體。由於創新生物特異性抗體的發現和一系列預期的產品發布活動，中國抗體檢測市場正在不斷擴大。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Viracta Therapeutics, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Atara Biotherapeutics, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • AlloVir, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按診斷分類的全球 Epstein-Barr 病毒診斷和治療市場
    • 基於實驗室的測試
    • 概念驗證測試
  • 按治療分類的全球 Epstein-Barr 病毒診斷和治療市場
    • 抗病毒藥物（阿昔洛韋、更昔洛韋、地昔洛韋）
    • 其他藥物（抗發炎、解熱等）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Advenchen Laboratories LLC
  • Arno Therapeutics Inc.
  • bluebird bio Inc.
  • Cell Medica Ltd.
  • Epiphany Biosciences Inc.
  • Genocea Biosciences Inc.
  • Omeros Corp.
  • TC BioPharm Ltd.
  • Theravectys SA
  • Viracta Therapeutics Inc.
  • Vironika LLC
  • ViroStatics srl
Product Code: OMR2027688

Title: Global Epstein - Barr Virus Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Treatment (Lab-Based Test and POC test), by Diagnosis (Antiviral Drugs, and Other Drugs),Forecast Period (2023-2030).

The global Epstein - Barr virus diagnosis and treatment market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period (2023-2030). The considerable prevalence of the Epstein-Barr virus (EBV) is a key factor creating demand for its treatment which in turn driving the global EBV diagnosis and treatment market. The EBV is a herpes virus that normally resides after infection as an organism in the epithelial tissues of the throat and lymphocytes. Most humans carry the virus and blood tests will often show low levels of EBV antibodies. Moreover, Multiple sclerosis (MS) is an incurable autoimmune disease that afflicts 2.8 million people worldwide. People diagnosed with MS experience progressive damage to their central nervous system and can lose about seven years of their life expectancy, according to the National Multiple Sclerosis Society. Researchers at the Harvard T.H. Chan School of Public Health determined that the biggest risk factor for contracting the disease may be previous infection with the Epstein-Barr virus (EBV).

Segmental Outlook

The global Epstein - Barr virus diagnosis and treatment market is segmented on the diagnosis, and treatment. Based on the diagnosis, the market is sub-segmented into lab-based test and POC test. Based on the treatment, the market is sub-segmented into antiviral drugs (Acyclovir, ganciclovir, desciclovir), and other drugs (Anti-inflammatory, Antipyretic and other). Among the diagnosis, the Point of care sub-segment is anticipated to hold a considerable share of the market Point-of-care testing tools have opened up a wide range of options in terms of the indications that can be diagnosed in settings other than a laboratory.

The Antiviral drug Sub-Segment is Anticipated to Hold a Considerable Share of the Global Epstein - Barr virus diagnosis and Treatment Market

Among the treatment, the antiviral test sub-segment is expected to hold a considerable share of the global Epstein - Barr virus diagnosis and Treatment market. Antiviral drugs are the most common drug given in case of infectious diseases and one the major infectious disease The infectious mononucleosis, also called "mono," is a contagious disease. EBV is the most common cause of infectious mononucleosis, but other viruses can also cause this disease. It is common among teenagers and young adults, especially college students. At least one out of four teenagers and young adults who get infected with EBV will develop infectious mononucleosis. A history of infection with EBV known for causing infectious mononucleosis, or mono, and certain types of cancer is believed to be the strongest risk factor for multiple sclerosis (MS).

Regional Outlook

The global Epstein - Barr virus diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe. The increasing autoimmune disease cases and the resulting increase in demand for antibody tests, as well as government initiatives to raise public awareness of the advantages of health insurance programs, are some of the key factors anticipated to propel the regional market growth.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Epstein - Barr virus diagnosis and Treatment Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to rise number of generic population and increase in number of clinical trials owing to rise in cases of new diseases in the region. In May 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has launched an early-stage clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV). EBV is the primary cause of infectious mononucleosis ("mono") and is associated with certain cancers and autoimmune diseases. The Phase 1 study is one of only two studies to test an investigational EBV vaccine in more than a decade. It will be conducted at the NIH Clinical Center in Bethesda, Maryland.

Hence, there is considerable shift of the country towards the adoption of the Epstein - Barr virus diagnosis and Treatment market solutions. According to the Indian Council of Medical Research, China sent 500,000 rapid antibody testing kits to India in April 2020. (ICMR). Additionally, Chinese R&D firms are concentrating more on developing bio-specific antibody tests whereas the majority of foreign firms are primarily concerned with anti-CD3 antibodies. The Chinese antibody testing market is expanding due to the discovery of innovative bio-specific antibodies and a number of anticipated product launch events.

Market Players Outlook

The major companies serving the Epstein - Barr virus diagnosis and treatment market include Advenchen Laboratories LLC, Arno Therapeutics Inc, bluebird bio Inc, Cell Medica Ltd, Epiphany Biosciences Inc, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2023, ModeX Therapeutics and Merck announced the collaboration, which is expected to advance the development of ModeX's MDX-2201, an investigational vaccine targeting the Epstein-Barr virus (EBV). Under the agreement, the two companies will work together to continue the preclinical development of MDX-2201. They also will collaborate to file an investigational new drug (IND) application with the US Food and Drug Administration requesting clearance to test the vaccine candidate for EBV in clinical trials.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Epstein - Barr virus diagnosis and Treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Viracta Therapeutics, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Atara Biotherapeutics, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. AlloVir, Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Epstein-Barr Virus diagnosis and Treatment Market by Diagnosis
    • 4.1.1. Lab based test
    • 4.1.2. POC Test
  • 4.2. Global Epstein-Barr Virus diagnosis and Treatment Market by Treatment
    • 4.2.1. Antiviral drugs (Acyclovir, ganciclovir, desciclovir)
    • 4.2.2. Other Drugs (Anti-inflammatory, Antipyretic and other)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advenchen Laboratories LLC
  • 6.2. Arno Therapeutics Inc.
  • 6.3. bluebird bio Inc.
  • 6.4. Cell Medica Ltd.
  • 6.5. Epiphany Biosciences Inc.
  • 6.6. Genocea Biosciences Inc.
  • 6.7. Omeros Corp.
  • 6.8. TC BioPharm Ltd.
  • 6.9. Theravectys SA
  • 6.10. Viracta Therapeutics Inc.
  • 6.11. Vironika LLC
  • 6.12. ViroStatics srl

LIST OF TABLES

  • 1. GLOBAL EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 2. GLOBAL LAB BASED TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL POC TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 5. GLOBAL ANTIVIRAL DRUGS FOR EPSTEIN-BARR VIRUS TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHER DRUGS FOR EPSTEIN-BARR VIRUS TREATMENT MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. NORTH AMERICAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 9. NORTH AMERICAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 10. NORTH AMERICAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 11. EUROPEAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 12. EUROPEAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 13. EUROPEAN EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 14. ASIA- PACIFIC EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. ASIA- PACIFIC EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 16. ASIA- PACIFIC EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)
  • 17. REST OF THE WORLD EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. REST OF THE WORLD EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2022-2030 ($ MILLION)
  • 19. REST OF THE WORLD EPSTEIN-BARR VIRUS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL EPSTEIN-BARR VIRUS MARKET SHARE BY DIAGNOSIS, 2022 VS 2030 (%)
  • 2. GLOBAL LAB BASED TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL POC TEST FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL EPSTEIN-BARR VIRUS MARKETSHARE BY TREATMENT, 2022 VS 2030 (%)
  • 5. GLOBAL ANTIVIRAL DRUGS FOR EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHER DRUGS EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKETSHARE BY REGION, 2022 VS 2030 (%)
  • 8. US EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 9. CANADA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 10. UK EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 11. FRANCE EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. GERMANY EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. ITALY EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. SPAIN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. REST OF EUROPE EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. INDIA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CHINA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. JAPAN EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. SOUTH KOREA EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. REST OF ASIA-PACIFIC EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. REST OF THE WORLD EPSTEIN-BARR VIRUS DIAGNOSIS AND TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)